You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Funding for Fluidigm's assay through NIH's RADx program was increased by approximately $22 million for a total contract value of up to about $34 million.
The company's contract with the NIH offered $12 million total and after initial test verification, Fluidigm will receive approximately $11 million.
The university also is developing a process for measuring phenotype risk scores as it continually adapts to changing technology and research needs.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
AWS joins Google Cloud in supporting STRIDES, a nascent NIH program aimed at reducing barriers to large-scale biomedical data analysis via cloud computing.
The All of Us Participant Technology Systems Center offers web and mobile apps to aggregate data and engage patients who join the All of Us cohort program.
During a two-year pilot, the Genomic Ascertainment Cohort will collect 10,000 genotypes and make patients available for follow-up exams to confirm predictions.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
The National Cancer Institute is accepting proposals from groups interested in producing affinity binders for the agency's Antibody Characterization Program.
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.
Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.